Celgene

Transdel Pharmaceuticals is a publicly traded company that specializes in developing noninvasive, topically delivered medications. Its patented Transdel cream formulation technology is designed to facilitate the penetration of drugs through the tough skin barrier to reach the target underlying tissues. The company is also developing drug candidates and treatments for transdermal delivery using Transdel platform technology for products in pain management and other therapeutic areas, as well as for cosmetic products. Transdel Pharmaceuticals also produces a topical drug, Ketotransdel.

Resolute Capital Partners Fund is a Nashville-based investment firm that specializes in providing structured capital solutions to lower-middle market companies. With a disciplined approach and a focus on creative financing, Resolute empowers businesses to envision bolder futures and scale successfully. Their portfolio reflects their expertise in various sectors, including healthcare services, business services, and niche manufacturing. Resolute Capital's success is attributed to their careful selection process, defined strategy, and hands-on approach. They primarily invest in companies with strong market positions, sustainable cash flows, growth potential, and exceptional management teams. Their typical investment ranges from $5 to $40 million in the form of subordinated debt and equity. Through transparency, ongoing collaboration, and personalized solutions, Resolute Capital aims to support the long-term success of their portfolio companies.Generated from the website